Stimulation of glucose transport in rat cardiac myocytes by guanosine 3',5'-monophosphate.
Glucose transport in isolated rat cardiomyocytes is stimulated by insulin, catecholamines, and anoxia approximately 2- to 3-fold over basal rates. The molecular mechanisms controlling these responses are unknown. In our search for possible cellular mediators of glucose transport stimulation, we examined the effects of a number of nucleotides on 3-O-methylglucose transport in heart cells. The nucleotides and/or permeable analogs (monosuccinyl, 8-bromo, and dibutyryl derivatives) included cUMP, cIMP, cCMP, cAMP, and cGMP at concentrations ranging from 10 nM to 1 mM. Of all the nucleotides tested only cGMP analogs induced a significant stimulation of transport at concentrations as low as 100 nM. This effect was observed in both the 8-bromo- and dibutyryl derivatives and with 1 mM cGMP itself. The effect was concentration dependent for both analogs and produced a maximal response equivalent to that of 100 nM insulin. This insulinomimetic effect of cGMP was examined in more detail in order to evaluate its role as a potential mediator of this response. Agents that are known to stimulate guanylate cyclase in the heart produced a clear stimulation of transport when added to cardiomyocytes. These include insulin, aminophylline, histamine, beta-estradiol, and biotin-nitrophenyl ester. Methylene blue, an inhibitor of guanylate cyclase, blocked the insulin response when added to cells before insulin, but was ineffective when added after insulin. In addition, agents that raise intracellular cGMP levels by inhibiting cyclic nucleotide phosphodiesterases were also examined for effects on glucose transport. Out of several phosphodiesterase inhibitors tested, only Zaprinast (which selectively increases cGMP in heart) stimulated transport in a concentration-dependent manner to within 80% of the maximal insulin effect. These results are consistent with the notion that cGMP may be involved in glucose transport stimulation.
Shanahan
M F
MF
Department of Physiology, Southern Illinois University School of Medicine, Carbondale 62901-6512.
Edwards
B M
BM
D000628:Aminophylline / Q000494:pharmacology; D000818:Animals; D000242:Cyclic AMP / Q000494:pharmacology; D003563:Cyclic CMP / Q000494:pharmacology; D006152:Cyclic GMP / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000502:physiology; D007289:Cyclic IMP / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D005947:Glucose / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology; D008751:Methylene Blue / Q000494:pharmacology; D009206:Myocardium / Q000166:cytology* / Q000378:metabolism; D009712:Nucleotides, Cyclic / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014542:Uridine Monophosphate / Q000494:pharmacology
D007328:Insulin; D009712:Nucleotides, Cyclic; D010726:Phosphodiesterase Inhibitors; D000628:Aminophylline; D007289:Cyclic IMP; D003563:Cyclic CMP; C045338:cyclic 3',5'-uridine monophosphate; D004958:Estradiol; D000242:Cyclic AMP; D014542:Uridine Monophosphate; D006152:Cyclic GMP; D005947:Glucose; D008751:Methylene Blue